Greytown Gazette

Breast cancer patients to consider colouring their recovery

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BREAST cancer is the most common invasive cancer in women, and one of the most common forms of cancer overall around the world. South Africa records the highest incidence rate for breast cancer, with a lifetime risk estimated at 1 in women.2 It is also important to note that, although rare, it has been recorded that 1 to 3% of South African men are also diagnosed with breast cancer.3

As such, Zogera Kara, Pfizer Category Lead for Vaccines, Oncology, Inflammation Immunology, said Pfizer Oncology is deeply committed to advancing scientific innovation and transforming the current state of breast cancer care for the millions of people around the world and in South Africa, who are affected by breast cancer every day.

Pfizer has a decades-long heritage in research and development, she says. “This, paired with an innovative use of technology and real-world evidence have accelerated our ability to deliver breakthrough therapies for those living with breast cancer.”

Support independent journalism
Get 14 days free to read all our investigative and in-depth journalism. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed.
Subscribe
Already a subscriber? Sign in
Rand - Dollar
15.76
+0.5%
Rand - Pound
19.83
+0.1%
Rand - Euro
16.84
-0.3%
Rand - Aus dollar
11.20
+0.1%
Rand - Yen
0.12
+0.9%
Gold
1,853.18
+0.4%
Silver
21.78
+0.1%
Palladium
2,002.00
+1.6%
Platinum
958.00
-0.1%
Brent Crude
112.55
+0.5%
Top 40
61,788
+1.3%
All Share
68,367
+1.2%
Resource 10
74,616
+2.8%
Industrial 25
73,018
+0.1%
Financial 15
15,916
+1.1%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE